Adjuvant Chemoradiotherapy With Epirubicin, Cisplatin, and Fluorouracil Compared With Adjuvant Chemoradiotherapy With Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance).
Explore this paper's citation graph
Summary
After a curative resection of gastric or gastroesophageal junction adenocarcinoma, postoperative chemoradiotherapy using a multiagent regimen of ECF before and after radiotherapy does not improve survival compared with standard FU and LV before and before radiotherapy.
- Type
- article
- Published
- 2017-10-04
- Cited by
- 116
- References
- 34
- Access
- Open access
- OpenAlex
- https://openalex.org/W2763640718
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:4855177
Keywords
Medicine, Fluorouracil, Chemoradiotherapy, Epirubicin, Hazard ratio
References
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- Randomized comparison of two schedules of fluorouracil and leucovorin in the treatment of advanced colorectal cancer.
- Patient survival after D 1 and D 2 resections for gastric cancer: long-term results of the MRC randomized surgical trial
- The University of North Carolina at Chapel Hill School of Medicine.
- Discrete sequential boundaries for clinical trials
- Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroœsophageal junction
- A Proportional Hazards Model for the Subdistribution of a Competing Risk
- D2 lymphadenectomy alone or with para-aortic nodal dissection for gastric cancer.
- A Class of K-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
- Patient survival after D1 and D2 resections for gastric cancer: long-term results of MRC randomized surgical trial
- Extended lymph-node dissection for gastric cancer.
- Extended lymph node dissection for gastric cancer: who may benefit? Final results of the randomized Dutch gastric cancer group trial.
- Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
- Comprehensive molecular characterization of gastric adenocarcinoma
- Refining the Role for Adjuvant Radiotherapy in Gastric Cancer: Risk Stratification Is Key.
- Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection.
- Phase III Trial to Compare Adjuvant Chemotherapy With Capecitabine and Cisplatin Versus Concurrent Chemoradiotherapy in Gastric Cancer: Final Report of the Adjuvant Chemoradiotherapy in Stomach Tumors Trial, Including Survival and Subset Analyses.
- [Extended lymph-node dissection for gastric cancer].
- Toxicity, surgical complications, and short-term mortality in a randomized trial of neoadjuvant cisplatin/5FU versus epirubicin/cisplatin and capecitabine prior to resection of lower esophageal/gastroesophageal junction (GOJ) adenocarcinoma (MRC OEO5, ISRCTN01852072, CRUK 02/010).
- A multicenter randomized phase III trial of neo-adjuvant chemotherapy followed by surgery and chemotherapy or by surgery and chemoradiotherapy in resectable gastric cancer: First results from the CRITICS study.
Cited by
- Current Targeted Therapies in HER2-Positive Gastric Adenocarcinoma
- Angiogenesis inhibitors in early development for gastric cancer
- Multimodality treatment of operable gastric and oesophageal adenocarcinoma: evaluating neoadjuvant, adjuvant and perioperative approaches
- Refining the management of resectable esophagogastric cancer: FLOT4, CRITICS, OE05, MAGIC-B and the promise of molecular classification.
- Reseziertes Magenkarzinom: Moderne Chemotherapie ist klassischer nicht überlegen
- Durvalumab in urothelial cancers
- A proteomic landscape of diffuse-type gastric cancer
- Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
- Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open-label, randomised phase 3 trial.
- Role of Adjuvant Chemoradiotherapy for Duodenal Cancer: An Updated Analysis of Long-Term Follow-Up from Single Institution
- Expression and prognostic value of cell-cycle-associated genes in gastric adenocarcinoma
- Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
- Peri-operative therapy for operable gastroesophageal adenocarcinoma: past, present and future
- Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)
- Locally advanced gastro-oesophageal cancer: Recent therapeutic advances and research directions.
- Functional variant of MTOR rs2536 and survival of Chinese gastric cancer patients
- Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer
- Gastrointestinal Cancers—Carving Out the Optimal Local Therapies in the Gastrointestinal Tract
- Gastric cancer: epidemiology, prevention, and therapy
- [Chemotherapy and chemoradiotherapy indications in the treatment of locally advanced gastric carcinoma].
Related papers
- Epirubicin, Cisplatin and Continuous-Infusion 5-Fluorouracil (ECF Regimen) in the Treatment of Advanced Colorectal Cancer
- Epirubicin, cisplatin and intermittent continuous infusion of 5-fluorouracil in advanced gastric cancer: an effective regimen?
- A pilot study of accelerated cyclophosphamide, epirubicin and 5-fluorouracil plus granulocyte colony stimulating factor as adjuvant therapy in early breast cancer.
- Prospective randomized study of cyclophosphamide, epirubicin, and 5-fluorouracil versus cyclophosphamide, adriamycin, and 5-fluorouracil in advanced or recurrent breast cancer
- A randomized, comparative study of combination chemotherapies in advanced gastric cancer: 5-fluorouracil and cisplatin (FP) versus 5-fluorouracil, cisplatin, and 4'-epirubicin (FPEPIR). Kyoto Research Group for Chemotherapy of Gastric Cancer (KRGCGC).
- Results of a phase II trial of epirubicin and cisplatin (EP) before and after irradiation and 5-fluorouracil in locally advanced pancreatic cancer: an EORTC GITCCG study.
- A Comparison of Navelbine Plus Cisplatin Regimen with and 5-Fluorouracil, Epirubicin. and Cyclophosphamide Regimen as Neoadjurant Chemotherapy in 122 Cases with Breast Cancer
- High rate of clinical complete response to weekly outpatient chemotherapy in oral carcinoma patients using a new regimen of cisplatin, 5-fluorouracil, and bleomycin alternating with methotrexate and epirubicin
- Adjuvant and neoadjuvant therapy for gastric cancer using epirubicin/cisplatin/5-fluorouracil (ECF) and alternative regimens before and after chemoradiation